Introduction: Breast sarcomas (BS) are rare malignant tumors with aggressive behavior and limited evidence guiding outcome assessment. Data on distant metastasis-free interval (DMFI) in this population are scarce. This study aimed to describe oncologic outcomes and clinicopathologic characteristics in patients with BS treated with curative intent. Methods: Patients with primary or secondary breast sarcoma treated at a single tertiary cancer center between 2013 and 2025 were retrospectively analyzed. Patients with metastatic disease at diagnosis were excluded. DMFI was the primary endpoint, and OS was the endpoint. Survival outcomes were estimated using Kaplan-Meier methodology and presented descriptively. Results: Twenty-six patients met the inclusion criteria. Angiosarcoma was the most common histologic subtype, predominantly occurring as secondary disease after prior breast radiotherapy. Median DMFI was not reached during follow-up, with 71.5% of patients remaining metastasis-free at 3 years, whereas median OS was 31 months with a 3-year OS of 46.9%. Patients with higher pathological T stage, larger tumors, tumor necrosis, younger age, and narrower resection margins tended to demonstrate shorter DMFI. Differences in overall survival were most pronounced according to resection margin status. Conclusions: Tumor burden-related factors, tumor necrosis, and surgical margin width showed clinically relevant differences in metastasis-related outcomes and survival in breast sarcoma. Adequate surgical resection remains critical in this rare and heterogeneous disease.
Buta et al. (Thu,) studied this question.